Thymic stromal lymphopoietin-stimulated CD4+ T cells induce senescence in advanced breast cancer

Thymic Stromal Lymphopoietin (TSLP) plays a prominent role in inducing type 2 immune response, commonly associated with atopic diseases. TSLP-activated CD4+ T helper 2 cells block early carcinogenesis by inducing terminal differentiation in spontaneous breast and lung cancer models. However, the impact of TSLP induction on advanced cancer with altered cellular phenotypes is unclear. Using an established MMTV-PyMttg breast cancer cell line, we demonstrate that TSLP-stimulated CD4+ T cells possess an antitumor effect in advanced breast cancer. In contrast to early breast cancer suppression, the antitumor immunity mediated by TSLP-stimulated CD4+ T cells in advanced breast cancer is mediated by the induction of a senescent-like phenotype in cancer cells. Inflammatory CD4+ T cells drive breast cancer cells into senescence by releasing interferon-gamma and tumor necrosis factor-alpha, which directly bind to their receptors on cancer cells. Our findings reveal a novel mechanism of TSLP-activated CD4+ T cell immunity against advanced breast cancer, mediated by cellular senescence as a distinct effector mechanism for cancer immunotherapy.

[1]  M. Rivera,et al.  CD4+ T helper 2 cells suppress breast cancer by inducing terminal differentiation , 2022, The Journal of experimental medicine.

[2]  S. Demehri,et al.  Thymic Stromal Lymphopoietin Induction Suppresses Lung Cancer Development , 2022, Cancers.

[3]  Kazuhiro Yoshida,et al.  Association of Th2 high tumors with aggressive features of breast cancer. , 2020 .

[4]  A. Hakimi,et al.  TGF-β suppresses type 2 immunity to cancer , 2020, bioRxiv.

[5]  G. Christofori,et al.  PyMT-1099, a versatile murine cell model for EMT in breast cancer , 2018, Scientific Reports.

[6]  B. Czerniecki,et al.  Oncodriver inhibition and CD4+ Th1 cytokines cooperate through Stat1 activation to induce tumor senescence and apoptosis in HER2+ and triple negative breast cancer: implications for combining immune and targeted therapies , 2018, Oncotarget.

[7]  Y. Suh,et al.  Age- and Tissue-Specific Expression of Senescence Biomarkers in Mice , 2018, Front. Genet..

[8]  S. Ziegler,et al.  A tumor-myeloid cell axis, mediated via interleukin 1α and TSLP, promotes breast cancer progression , 2018, Nature Immunology.

[9]  B. Bogen,et al.  Adoptive Transfer of Tumor-Specific Th2 Cells Eradicates Tumors by Triggering an In Situ Inflammatory Immune Response. , 2016, Cancer research.

[10]  J. Belizário,et al.  Thymic and Postthymic Regulation of Naïve CD4+ T-Cell Lineage Fates in Humans and Mice Models , 2016, Mediators of inflammation.

[11]  W. Yokoyama,et al.  Thymic stromal lymphopoietin blocks early stages of breast carcinogenesis. , 2016, The Journal of clinical investigation.

[12]  V. Golubovskaya,et al.  Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy , 2016, Cancers.

[13]  B. Fingleton,et al.  Interleukin-5 facilitates lung metastasis by modulating the immune microenvironment. , 2015, Cancer research.

[14]  L. Zender,et al.  T-helper-1-cell cytokines drive cancer into senescence , 2013, Nature.

[15]  S. Ziegler.  Thymic stromal lymphopoietin and allergic disease. , 2012, The Journal of allergy and clinical immunology.

[16]  George Coukos,et al.  Cancer immunotherapy comes of age , 2011, Nature.

[17]  W. Leonard,et al.  Thymic Stromal Lymphopoietin Is a Key Mediator of Breast Cancer Progression , 2011, The Journal of Immunology.

[18]  C. Aspord,et al.  Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation , 2011, The Journal of experimental medicine.

[19]  K. Chin,et al.  A Human-Like Senescence-Associated Secretory Phenotype Is Conserved in Mouse Cells Dependent on Physiological Oxygen , 2010, PloS one.

[20]  J. Campisi,et al.  The senescence-associated secretory phenotype: the dark side of tumor suppression. , 2010, Annual review of pathology.

[21]  L. Coussens,et al.  CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. , 2009, Cancer cell.

[22]  W. Paul,et al.  CD4 T cells: fates, functions, and faults. , 2008, Blood.

[23]  Yong‐jun Liu,et al.  Thymic stromal lymphopoietin: master switch for allergic inflammation , 2006, The Journal of experimental medicine.

[24]  Yu Wang,et al.  TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand , 2005, The Journal of experimental medicine.

[25]  W. Leonard,et al.  A role for TSLP in the development of inflammation in an asthma model , 2005, The Journal of experimental medicine.

[26]  S. Szabo,et al.  Molecular mechanisms regulating Th1 immune responses. , 2003, Annual review of immunology.

[27]  P. Foster,et al.  Immunotherapy of Cytotoxic T Cell–resistant Tumors by T Helper 2 Cells , 2003, The Journal of experimental medicine.

[28]  A. Ohta,et al.  Distinct Role of Antigen-Specific T Helper Type 1 (Th1) and Th2 Cells in Tumor Eradication in Vivo , 1999, The Journal of experimental medicine.

[29]  P. Allavena,et al.  Differential Expression of Chemokine Receptors and Chemotactic Responsiveness of Type 1 T Helper Cells (Th1s) and Th2s , 1998, The Journal of experimental medicine.

[30]  B. Hargadon,et al.  Increased expression of immunoreactive thymic stromal lymphopoietin in patients with severe asthma. , 2012, The Journal of allergy and clinical immunology.

[31]  S. Constant,et al.  Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. , 1997, Annual review of immunology.